{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:06:54Z","timestamp":1790006814002,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Technical Service Platform of Drug Solid State and Quality Control","award":["23DZ2292600"],"award-info":[{"award-number":["23DZ2292600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11095-026-04116-1","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T18:53:34Z","timestamp":1779994414000},"page":"2923-2940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Crystal Structure to Dissolution Enhancement: Cocrystal Engineering of Resmetirom to Address Its Solubility Challenge"],"prefix":"10.1007","volume":"43","author":[{"given":"Chen","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangkui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-1090","authenticated-orcid":false,"given":"Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"4116_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1109615","volume":"14","author":"S Lin","year":"2023","unstructured":"Lin S, Huang S, Deng Z, Zhang Y, Huang L, Wu Y, et al. Discovery of a novel, liver-targeted thyroid hormone receptor-\u03b2 agonist, CS271011, in the treatment of lipid metabolism disorders. Front Endocrinol. 2023;14:1109615. https:\/\/doi.org\/10.3389\/fendo.2023.1109615.","journal-title":"Front Endocrinol"},{"issue":"6","key":"4116_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Resmetirom: first approval. Drugs. 2024;84(6):729\u201335. https:\/\/doi.org\/10.1007\/s40265-024-02045-0.","journal-title":"Drugs"},{"key":"4116_CR3","unstructured":"Madrigal Pharmaceuticals Inc., 2024. Resmetirom: US prescribing information. https:\/\/www.rezdiffra.com\/. Accessed 18 Mar 2024."},{"issue":"6","key":"4116_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"N Engl J Med"},{"issue":"10213","key":"4116_CR5","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(19)32517-6.","journal-title":"Lancet"},{"issue":"7","key":"4116_CR6","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/liv.15930","volume":"44","author":"S Petta","year":"2024","unstructured":"Petta S, Targher G. The first MASH drug therapy on the horizon: current perspectives of resmetirom. Liver Int. 2024;44(7):1526\u201336. https:\/\/doi.org\/10.1111\/liv.15930.","journal-title":"Liver Int"},{"issue":"32","key":"4116_CR7","doi-asserted-by":"publisher","first-page":"22172","DOI":"10.1039\/d3ra02521g","volume":"13","author":"C Liu","year":"2023","unstructured":"Liu C, Xu Y, Yuan H, Tian G, Qin X, Lou B, et al. Solubility determination, dissolution properties and solid transformation of resmetirom (form A) in heptane and seven alcohols. RSC Adv. 2023;13(32):22172\u201384. https:\/\/doi.org\/10.1039\/d3ra02521g.","journal-title":"RSC Adv"},{"key":"4116_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/B978-0-444-53242-8.00018-7","volume-title":"Developing solid oral dosage forms: pharmaceutical theory and practice","author":"X He","year":"2009","unstructured":"He X. Integration of physical, chemical, mechanical, and biopharmaceutical properties in solid oral dosage form development. In: Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter WR, editors. Developing solid oral dosage forms: pharmaceutical theory and practice. Boston: Academic Press; 2009. p. 407\u201341. https:\/\/doi.org\/10.1016\/B978-0-444-53242-8.00018-7."},{"issue":"1\u20132","key":"4116_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijpharm.2017.10.003","volume":"535","author":"SV Jermain","year":"2018","unstructured":"Jermain SV, Brough C. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery\u2014an update. Int J Pharm. 2018;535(1\u20132):379\u201392. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.10.003.","journal-title":"Int J Pharm"},{"key":"4116_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.104967","volume":"137","author":"BJ Boyd","year":"2019","unstructured":"Boyd BJ. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci. 2019;137:104967. https:\/\/doi.org\/10.1016\/j.ejps.2019.104967.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"4116_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1557\/mrs2006.206","volume":"31","author":"W Jones","year":"2006","unstructured":"Jones W, Motherwell S. Pharmaceutical cocrystals: an emerging approach to physical property enhancement. MRS Bull. 2006;31(11):875\u20139. https:\/\/doi.org\/10.1557\/mrs2006.206.","journal-title":"MRS Bull"},{"issue":"10","key":"4116_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102198","volume":"14","author":"F Xiao","year":"2022","unstructured":"Xiao F, Cheng Y, Wang JR, Wang D, Zhang Y, Chen K, et al. Cocrystal prediction of bexarotene by graph convolution network and bioavailability improvement. Pharmaceutics. 2022;14(10):2198. https:\/\/doi.org\/10.3390\/pharmaceutics14102198.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4116_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020429","volume":"14","author":"MJ Lee","year":"2022","unstructured":"Lee MJ, Kim JY. Novel cocrystals of vonoprazan: machine learning-assisted discovery. Pharmaceutics. 2022;14(2):429. https:\/\/doi.org\/10.3390\/pharmaceutics14020429.","journal-title":"Pharmaceutics"},{"issue":"8","key":"4116_CR14","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1039\/c3cc47521b","volume":"50","author":"S Cherukuvada","year":"2014","unstructured":"Cherukuvada S, Nangia A. Eutectics as improved pharmaceutical materials: design, properties and characterization. Chem Commun (Camb). 2014;50(8):906\u201323. https:\/\/doi.org\/10.1039\/c3cc47521b.","journal-title":"Chem Commun (Camb)"},{"issue":"5","key":"4116_CR15","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1021\/cg3002948","volume":"12","author":"S Aitipamula","year":"2012","unstructured":"Aitipamula S, Banerjee R. Polymorphs, salts and cocrystals: what\u2019s in a name? Cryst Growth Des. 2012;12(5):2147\u201352. https:\/\/doi.org\/10.1021\/cg3002948.","journal-title":"Cryst Growth Des"},{"issue":"6","key":"4116_CR16","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1021\/acs.cgd.1c00211","volume":"21","author":"JJ Devogelaer","year":"2021","unstructured":"Devogelaer JJ, Charpentier MD. Cocrystals of praziquantel: discovery by network-based link prediction. Cryst Growth Des. 2021;21(6):3428\u201337. https:\/\/doi.org\/10.1021\/acs.cgd.1c00211.","journal-title":"Cryst Growth Des"},{"issue":"9","key":"4116_CR17","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1021\/acs.cgd.2c00615","volume":"22","author":"D Jan-Joris","year":"2022","unstructured":"Jan-Joris D. Comparing and quantifying the efficiency of cocrystal screening methods for praziquantel. Cryst Growth Des. 2022;22(9):5511\u201325. https:\/\/doi.org\/10.1021\/acs.cgd.2c00615.","journal-title":"Cryst Growth Des"},{"issue":"4","key":"4116_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.15171\/apb.2019.064","volume":"9","author":"R Al-Kazemi","year":"2019","unstructured":"Al-Kazemi R, Al-Basarah Y, Nada A. Dissolution enhancement of atorvastatin calcium by cocrystallization. Adv Pharm Bull. 2019;9(4):559\u201370. https:\/\/doi.org\/10.15171\/apb.2019.064.","journal-title":"Adv Pharm Bull"},{"issue":"5","key":"4116_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050618","volume":"13","author":"H Kim","year":"2021","unstructured":"Kim H, Jang S. Enhanced dissolution of Naproxen by combining cocrystallization and eutectic formation. Pharmaceutics. 2021;13(5):618. https:\/\/doi.org\/10.3390\/pharmaceutics13050618.","journal-title":"Pharmaceutics"},{"issue":"11","key":"4116_CR20","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1021\/acs.molpharmaceut.5b00642","volume":"12","author":"AO Surov","year":"2015","unstructured":"Surov AO, Manin AN, Churakov AV, Perlovich GL. New solid forms of the antiviral drug arbidol: crystal structures, thermodynamic stability, and solubility. Mol Pharm. 2015;12(11):4154\u201365. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00642.","journal-title":"Mol Pharm"},{"key":"4116_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118776","volume":"572","author":"JY Chen","year":"2019","unstructured":"Chen JY, Wu H, Guo CY, Zhu B, Ren GB. Enhancing the solubility of natural compound Xanthotoxin by modulating stability via cocrystallization engineering. Int J Pharm. 2019;572:118776. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118776.","journal-title":"Int J Pharm"},{"issue":"1","key":"4116_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1073\/pnas.36.1.7","volume":"36","author":"JH Hildebrand","year":"1950","unstructured":"Hildebrand JH. Factors determining solubility among non-electrolytes. Proc Natl Acad Sci U S A. 1950;36(1):7\u201315. https:\/\/doi.org\/10.1073\/pnas.36.1.7.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"4116_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/pen.760140211","volume":"14","author":"RF Fedors","year":"1974","unstructured":"Fedors RF. A method for estimating both the solubility parameters and molar volumes of liquids. Polym Eng Sci. 1974;14(2):147\u201354. https:\/\/doi.org\/10.1002\/pen.760140211.","journal-title":"Polym Eng Sci"},{"issue":"4","key":"4116_CR24","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.22377\/ajp.v10i04.902","volume":"10","author":"SL Patwekar","year":"2016","unstructured":"Patwekar SL. Nanobiocomposite: a new approach to drug delivery system. Asian J Pharm. 2016;10(4):S746\u201352. https:\/\/doi.org\/10.22377\/ajp.v10i04.902.","journal-title":"Asian J Pharm"},{"key":"4116_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2024.105885","volume":"99","author":"N Fujiwara","year":"2024","unstructured":"Fujiwara N, Ito L. Predicting the binding affinity of chemicals to estrogen receptor using Hansen solubility parameters. Toxicol In Vitro. 2024;99:105885. https:\/\/doi.org\/10.1016\/j.tiv.2024.105885.","journal-title":"Toxicol In Vitro"},{"key":"4116_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ijpharm.2019.01.007","volume":"558","author":"A Salem","year":"2019","unstructured":"Salem A, Nagy S, P\u00e1l S, Sz\u00e9chenyi A. Reliability of the Hansen solubility parameters as co-crystal formation prediction tool. Int J Pharm. 2019;558:319\u201327. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.01.007.","journal-title":"Int J Pharm"},{"issue":"11","key":"4116_CR27","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1021\/js9900856","volume":"88","author":"DJ Greenhalgh","year":"1999","unstructured":"Greenhalgh DJ, Williams AC, Timmins P. Solubility parameters as predictors of miscibility in solid dispersions. J Pharm Sci. 1999;88(11):1182\u201390. https:\/\/doi.org\/10.1021\/js9900856.","journal-title":"J Pharm Sci"},{"issue":"5","key":"4116_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.35333\/jrp.2020.226","volume":"24","author":"HR Trivedi","year":"2020","unstructured":"Trivedi HR, Patel JK, Shah S. Experimental design approach for development of cocrystals and immediate release cocrystal tablet of atorvastatin calcium for enhancement of solubility and dissolution. J Res Pharm. 2020;24(5):685\u201398. https:\/\/doi.org\/10.35333\/jrp.2020.226.","journal-title":"J Res Pharm"},{"issue":"1","key":"4116_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/15421406.2019.1577462","volume":"667","author":"S Kumar","year":"2019","unstructured":"Kumar S. Approaches to design of pharmaceutical cocrystals: a review. Mol Cryst Liq Cryst. 2019;667(1):54\u201377. https:\/\/doi.org\/10.1080\/15421406.2019.1577462.","journal-title":"Mol Cryst Liq Cryst"},{"issue":"4","key":"4116_CR30","doi-asserted-by":"publisher","first-page":"S715","DOI":"10.22377\/ajp.v11i04.1627","volume":"11","author":"P Santosh","year":"2017","unstructured":"Santosh P. Three-dimensional Hansen solubility parameters as predictors of miscibility in cocrystal formation. Asian J Pharm. 2017;11(4):S715\u201322. https:\/\/doi.org\/10.22377\/ajp.v11i04.1627.","journal-title":"Asian J Pharm"},{"issue":"3","key":"4116_CR31","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1021\/mp050099m","volume":"3","author":"N Rodr\u00edguez-Hornedo","year":"2006","unstructured":"Rodr\u00edguez-Hornedo N, Nehm SJ, Seefeldt KF, Pagan-Torres Y, Falkiewicz CJ. Reaction crystallization of pharmaceutical molecular complexes. Mol Pharm. 2006;3(3):362\u20137.","journal-title":"Mol Pharm"},{"issue":"1","key":"4116_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1107\/S0108767307043930","volume":"64","author":"GM Sheldrick","year":"2008","unstructured":"Sheldrick GM. A short history of SHELX. Acta Crystallogr A. 2008;64(1):112\u201322. https:\/\/doi.org\/10.1107\/S0108767307043930.","journal-title":"Acta Crystallogr A"},{"issue":"2","key":"4116_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1107\/S0021889808042726","volume":"42","author":"OV Dolomanov","year":"2009","unstructured":"Dolomanov OV, Bourhis LJ. OLEX2: a complete structure solution, refinement and analysis program. J Appl Crystallogr. 2009;42(2):339\u201341. https:\/\/doi.org\/10.1107\/S0021889808042726.","journal-title":"J Appl Crystallogr"},{"key":"4116_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2025.127568","volume":"287","author":"C Yang","year":"2025","unstructured":"Yang C, Luo Y. Comparison of resmetirom quantitative analysis in API and formulation models based on PXRD, FTIR and Raman scanning imaging combined with univariate and multivariate analyses. Talanta. 2025;287:127568. https:\/\/doi.org\/10.1016\/j.talanta.2025.127568.","journal-title":"Talanta"},{"key":"4116_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2022.120857","volume":"369","author":"GX Tian","year":"2023","unstructured":"Tian GX, Luo Y. Screening, packing systematics, Hansen solubility parameters and desolvation of resmetirom (MGL-3196) solvates. J Mol Liq. 2023;369:120857. https:\/\/doi.org\/10.1016\/j.molliq.2022.120857.","journal-title":"J Mol Liq"},{"issue":"1","key":"4116_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1039\/B818330A","volume":"11","author":"MA Spackman","year":"2009","unstructured":"Spackman MA, Jayatilaka D. Hirshfeld surface analysis. CrystEngComm. 2009;11(1):19\u201332. https:\/\/doi.org\/10.1039\/B818330A.","journal-title":"CrystEngComm"},{"issue":"6","key":"4116_CR37","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1021\/cg900129f","volume":"9","author":"N Schultheiss","year":"2009","unstructured":"Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9(6):2950\u201367. https:\/\/doi.org\/10.1021\/cg900129f.","journal-title":"Cryst Growth Des"},{"key":"4116_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.137756","volume":"1305","author":"S Allu","year":"2024","unstructured":"Allu S, An JH, Park B. Improving dissolution rate and solubility of palbociclib salts\/cocrystal for anticancer efficacy. J Mol Struct. 2024;1305:137756. https:\/\/doi.org\/10.1016\/j.molstruc.2024.137756.","journal-title":"J Mol Struct"},{"key":"4116_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2025.144855","author":"Y Jia","year":"2026","unstructured":"Jia Y, Xing C, Xie Y. Structural and mechanistic investigation of Piroxicam-Temozolomide and Tenoxicam-Temozolomide cocrystal formation. J Mol Struct. 2026. https:\/\/doi.org\/10.1016\/j.molstruc.2025.144855.","journal-title":"J Mol Struct"},{"issue":"3","key":"4116_CR40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1211\/0022357021778529","volume":"54","author":"AM Healy","year":"2002","unstructured":"Healy AM, McCarthy LG. Sensitivity of dissolution rate to location in the paddle dissolution apparatus. J Pharm Pharmacol. 2002;54(3):441\u20134. https:\/\/doi.org\/10.1211\/0022357021778529.","journal-title":"J Pharm Pharmacol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04116-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04116-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04116-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:47:17Z","timestamp":1790005637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04116-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4116"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04116-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}